ArticleCureus2026
Association of Vitamin B12 and Ferritin Levels With Neuropathic Pain and Disease Severity in Fibromyalgia Syndrome.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFibromyalgia syndrome (FMS) is a chronic disorder characterized by widespread musculoskeletal pain, often accompanied by fatigue, sleep disturbance, and cognitive impairment. Neuropathic pain is an important but underrecognized component of FMS, which significantly worsens disease burden. Micronutrient deficiencies, particularly serum vitamin B12 and ferritin, are suggested to influence pain perception and neuronal function, yet their role in FMS remains unclear, especially in Pakistan.
objectivesTo determine the association of serum vitamin B12 and ferritin levels with neuropathic pain and disease severity in patients with fibromyalgia. STUDY DESIGN AND
settingA cross-sectional analytical study conducted at the Department of Medicine, Shaikh Zayed Hospital, Lahore, Pakistan, from January to June 2025. METHODOLOGY: A total of 241 patients fulfilling the American College of Rheumatology (ACR 2016) criteria for FMS were enrolled. Demographic data, Fibromyalgia Impact Questionnaire-Revised (FIQR) scores, and Douleur Neuropathique en 4 Questions (DN4) scores were recorded. Serum vitamin B12 and ferritin levels were measured. Independent sample t-test and chi-square test were applied for comparisons, and multivariable logistic regression was performed to identify predictors of neuropathic pain, with p < 0.05 considered significant.
resultsMean age of participants was 46.0 ± 15.6 years, with female predominance (77.6%). Neuropathic pain was present in 58.5% of cases. Patients with neuropathic pain had significantly higher FIQR (52.7 ± 9.5 vs. 41.0 ± 8.9, p < 0.001) and DN4 scores (5.8 ± 1.4 vs. 2.8 ± 1.0, p < 0.001). Serum vitamin B12 and ferritin levels were lower in neuropathic patients (p = 0.001 and p = 0.005, respectively). Multivariable regression identified FIQR score as the strongest predictor of neuropathic pain (OR = 1.159, 95% CI: 1.112-1.208, p < 0.001).
conclusionNeuropathic pain is highly prevalent in FMS and is strongly associated with disease severity. Although vitamin B12 and ferritin showed lower levels in affected patients, only disease severity independently predicted neuropathic pain. Larger longitudinal studies are warranted to clarify causal pathways and therapeutic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.